<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-142231</identifier>
<setSpec>0212-1611</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Predictive factors of non-alcoholic steatohepatitis: relationship with metabolic syndrome</dc:title>
<dc:description xml:lang="en">Non-alcoholic fatty liver disease (NAFLD) has been proposed as the hepatic manifestation of the metabolic syndrom (Ms), with insulin resistance (IR) as the common pathophysiological mechanism. Methods: we included 145 patients with NAFLD proven liver biopsy. NAS-score was employed to grading NAFLD. We determined anthropometric measurements, basal blood pression (BP), biochemical measurements including high lipoprotein cholesterol (HDL-Chol), low-density lipoprotein cholesterol (LDL-Chol), triglycerides and leptin levels, homeostasis model assessment index (HOMA&#150;IR), and abdominal ultrasound scan (US) was performed. Diagnosis of Ms was performed based on ATP III criteria. Results: average age was 43.6 + 11.2 years old and the mean body mass index (BMI) was 39 ± 10.7 kg/m2 . Sex distribution was: females 66 and males 79. Forty patients (27.5%) presented a NAS score &gt; = 5. Waist circumference (p = 0.007), systolic and diastolic BP (p = 0.002 and p = 0.003 respectively), (HOMA-IR) (p = 5. Independent factors associated to NAS-score &gt; = 5 were Ms and BMI &gt; 30. Leptin levels were higher in patients with advanced fibrosis (&amp;#8805; F2) compared to patients with mild fibrosis (F0-F1) (75.5 + 50.2 ng/ml vs - 39.7 + 38.4 ng/ml respectively; p = 0.002). Conclusion: presence of Ms and obesity (BMI &gt;30) are the principal independent factors associated to NASH (NAS score &gt; = 5). Leptin levels and BMI are higher in patients with advanced fibrosis (AU)</dc:description>
<dc:creator>Luis, Daniel A de</dc:creator>
<dc:creator>Ruiz-Rebollo, Lourdes</dc:creator>
<dc:creator>Pacheco, David</dc:creator>
<dc:creator>Aller, Rocío</dc:creator>
<dc:creator>Izaola, Olatz</dc:creator>
<dc:language>en</dc:language>
<dc:description xml:lang="es">La esteatohepatitis no alcohólica (EHNA) se ha propuesto como la manifestación hepática del síndrome metabólico (SM), con la resistencia a la insulina (IR) como mecanismo fisiopatológico común. Métodos: se incluyeron 145 pacientes con biopsia hepática con enfermedad por hígado graso no alcohólica. NAS-score se utilizó para graduar la EHNA. Se realizaron las siguientes determinaciones; antropometría, presión arterial basal (BP), LDL colesterol, HDL colesterol, triglicéridos, leptina, resistencia a la insulina (HOMA-IR) y ecografía abdominal. El diagnóstico de síndrome metabólico se realizó en base a los criterios del ATP III. Resultados: la edad fue 43,6 + 11,2 años y la media de índice de masa corporal (IMC) 39 + 10.7 kg/ m2 (66 mujeres y 79 varones). Cuarenta pacientes (27,5%) presentaron una puntuación NAS&gt; = 5. La circunferencia de la cintura (p = 0,007), la presión arterial sistólica y diastólica (p = 0,002 y p = 0,003, respectivamente, la resistencia a la insulina (HOMA-IR) (p = 5. Los factores independientes asociados a NAS-score &gt; = 5 fueron el SM y el IMC &gt; 30. Los niveles de leptina fueron mayores en pacientes con fibrosis avanzada (&amp;#8805; F2) en comparación con los pacientes con fibrosis leve (F0-F1) (75,5 + 50,2 ng / ml frente a 39,7 + 38,4 ng / ml, respectivamente; p = 0.002). Conclusión: la presencia de SM y obesidad (IMC&gt; 30) son los principales factores independientes asociados a la EHNA (puntuación NAS&gt; = 5). Los niveles de leptina y el IMC son mayores en los pacientes con fibrosis avanzada (AU)</dc:description>
<dc:source>Nutr Hosp;31(6): 2496-2502, jun. 2015.</dc:source>
<dc:identifier>ibc-142231</dc:identifier>
<dc:title xml:lang="es">Factores predictivos de esteatohepatitis no alcohólica: papel del síndrome metabólico</dc:title>
<dc:subject>^d36032^s22032</dc:subject>
<dc:subject>^d50524^s22080</dc:subject>
<dc:subject>^d23568^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9951^s22080</dc:subject>
<dc:subject>^d24542</dc:subject>
<dc:subject>^d52657^s22031</dc:subject>
<dc:subject>^d34404^s22002</dc:subject>
<dc:subject>^d5337^s22032</dc:subject>
<dc:type>article</dc:type>
<dc:date>201506</dc:date>
</metadata>
</record>
</ibecs-document>
